Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.

Spiera, Robert; Jinich, Sarah; Jannat-Khah, Deanna

Spiera, Robert; Jinich, Sarah; Jannat-Khah, Deanna.

Spiera R; Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA spierar@hss.edu.
Jinich S; Department of Medicine, Division of Rheumatology, Weill Cornell Medical College, New York, New York, USA.
Jannat-Khah D; Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.

Ann Rheum Dis ; 80(10): 1357-1359, 2021 10.

Article in English | MEDLINE | ID: covidwho-1225699

Subject(s)

Antirheumatic Agents/therapeutic use; COVID-19 Vaccines/immunology; COVID-19/prevention & control; Immunogenicity, Vaccine/drug effects; Rituximab/therapeutic use; Adult; Aged; Antibodies, Viral/blood; Antibodies, Viral/immunology; COVID-19/immunology; COVID-19 Vaccines/therapeutic use; Female; Humans; Immunocompromised Host/immunology; Male; Middle Aged; Retrospective Studies; Rheumatic Diseases/drug therapy; Rheumatic Diseases/immunology; SARS-CoV-2

Keywords

COVID-19; antirheumatic agents; rituximab; vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antirheumatic Agents / Rituximab / Immunogenicity, Vaccine / COVID-19 Vaccines / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2021-220604

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google